Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Completes Enrollment in Cancer Drug Trial

Premium

Alnylam Pharmaceuticals said this week that it has completed enrollment in a phase I trial of its siRNA-based cancer drug ALN-VSP.

ALN-VSP was administered to more than 40 patients with advanced solid tumors with liver involvement at doses ranging from 0.1 to 1.5 mg/kg, with multiple patients continuing to receive therapy on the study, the company said.

Data are scheduled to be presented at the American Society of Clinical Oncology meeting in Chicago June 3 to 7.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.